{"id":"half-dose-ticagrelor","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Ventricular pauses"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that blocks ADP-induced platelet activation more rapidly and potently than other P2Y12 inhibitors. The half-dose formulation reduces the standard therapeutic dose to potentially minimize bleeding risk while maintaining antiplatelet efficacy. This approach is being evaluated in clinical settings to optimize the benefit-risk profile in acute coronary syndrome and other thrombotic conditions.","oneSentence":"Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:25.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS)"},{"name":"Secondary prevention of thrombotic cardiovascular events"}]},"trialDetails":[{"nctId":"NCT06486363","phase":"PHASE4","title":"Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-08-01","conditions":"Intracranial Aneurysms, Antiplatelet Drugs","enrollment":196},{"nctId":"NCT02944123","phase":"PHASE3","title":"Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-09","conditions":"Acute Coronary Syndrome","enrollment":120},{"nctId":"NCT02086903","phase":"PHASE3","title":"Clopidogrel And Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2014-02","conditions":"Pharmacodynamics","enrollment":12},{"nctId":"NCT03381755","phase":"PHASE4","title":"Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-01-01","conditions":"Acute Coronary Syndrome","enrollment":200},{"nctId":"NCT03614832","phase":"PHASE4","title":"Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-05-01","conditions":"Platelet Reactivity","enrollment":100},{"nctId":"NCT03062462","phase":"PHASE2, PHASE3","title":"Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2017-02-10","conditions":"Coronary Artery Disease, Clopidogrel, Poor Metabolism of","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"half-dose ticagrelor","genericName":"half-dose ticagrelor","companyName":"First Affiliated Hospital of Harbin Medical University","companyId":"first-affiliated-hospital-of-harbin-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events. Used for Acute coronary syndrome (ACS), Secondary prevention of thrombotic cardiovascular events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}